The purpose of this study is to evaluate the efficacy and safety of chemotherapy with Lobaplatin and 5-FU, in Recurrent Local or Distant Advanced Nasopharyngeal Carcinoma.

Inclusion Criteria:

• NPC diagnosed by pathology, with measurable lesions and imaging results, such as MRI and CT. Patients with no other lesions but bone metastasis are excluded.
• Recurrent locally or distant advanced NPC (rT3-4N0-3M0-1)
• ECOG 0 or 1
• Expected survival ≥ 1 year
• Without dysfunction of heart, lung, liver, kidney and hematopoiesis
• Patients are voluntary and signed informed consent
• No other anti-tumor treatment (including steroid)

Exclusion Criteria:

• Allergy history to platinum
• Use of 5-FU in last 6 months
• Had major surgery in last 4 weeks, or the wound has not completely healed
• Toxicity from previous treatment is still ≥CTC AE grade 3
• History of other carcinoma in the past 5 years, except for treated carcinoma in situ of cervix, as well as basal cell carcinoma or squamous cell carcinoma of the skin
• Dysfunction of heart
• Bleeding ≥CTC AE grade 3
• Use of anticoagulant or vitamin K antagonists, except for small dose of aspirin and warfarin for prevention
• Patients participated in clinical trials of other drugs within last 4 weeks
• Mental illness